You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
人福醫藥(600079.SH):子公司萘普生鈉片獲得藥品註冊證書
格隆匯 12-06 15:34

格隆匯12月6日丨人福醫藥(600079.SH)公佈,公司控股子公司宜昌人福藥業有限責任公司(“宜昌人福”,公司持有其80%的股權)近日收到國家藥品監督管理局核准簽發的萘普生鈉片的《藥品註冊證書》。

萘普生鈉片為鎮痛類藥物,用於暫時緩解輕微的疼痛,包括關節炎輕微疼痛、肌肉痠痛、背痛、月經抽筋、頭痛、牙痛、普通感冒及暫時退熱等。

宜昌人福的萘普生鈉片於2019年8月獲得FDA批准,於2019年11月向國家藥品監督管理局提交了該藥品的註冊申請並獲得受理,截至目前該項目累計研發投入約為1300萬元人民幣。

根據米內網數據顯示,2020年萘普生所有劑型在我國城市、縣級及鄉鎮三大終端公立醫院的銷售額約為人民幣1億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account